Corcept Therapeutics Executive Plans $1.3M Stock Sale Under Rule 144

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) – Form 144 filing. President Sean Maduck has filed to sell 20,000 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. At the 07/31/25 reference price, the sale is valued at $1.34 million. The shares were just acquired the same day via stock-option exercise; therefore the transaction is likely part of routine option monetisation.

Maduck has already disposed of 64,403 shares during the past three months for ~$4.79 million in gross proceeds. After the proposed trade, cumulative sales disclosed in the filing period reach ~84 k shares. CORT has 106.04 million shares outstanding, making the new sale ~0.02 % of outstanding stock and therefore not materially dilutive. No earnings, guidance or operational data are provided; this notice is strictly an insider-sale disclosure.

Positive

• None.

Negative

• Insider continues to liquidate shares – 64,403 shares sold in prior 3 months plus 20,000 planned may be viewed as a weak confidence signal.

Insights

Financial Analyst

TL;DR: Small insider sale (~0.02 % O/S); routine option exercise, limited market impact.

The filing signals a planned disposition rather than a strategic shift. While insider selling can be perceived negatively, the volume is immaterial compared with CORT’s 106 m share base and follows prior option-related sales. No adverse operational information is referenced, and Form 144 expressly requires the filer to confirm no undisclosed material events. I rate the impact neutral; liquidity implications or signalling effects are minimal.

Corporate Governance Specialist

TL;DR: Routine compliance disclosure; no governance red flags detected.

The seller certifies awareness of Rule 144 and fraud provisions, suggesting standard compliance. Frequency of recent sales (4 transactions in July alone) may draw investor attention, but volumes remain well below thresholds that typically trigger governance concerns. Absence of a disclosed 10b5-1 plan date limits visibility on pre-arranged trading, yet not required. Overall, the event is non-material for governance risk.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St. Louis MO 63102	20000	1343000.00	106040000	08/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2025	Stock Option Exercise	Corcept Therapeutics Inc.			20000	08/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	05/01/2025	12856	924817.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	20000	1581686.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	05/02/2025	26554	1917950.00
Sean Maduck 101 Redwood Shores Parkway Redwood Ciity CA 94065	Common	07/01/2025	205	15058.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	4315	317054.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	473	34747.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Corcept Therapeutics (CORT) shares are being sold in this Form 144?

The filer proposes to sell 20,000 common shares.

What is the estimated value of the shares to be sold?

The aggregate market value is approximately $1.34 million.

Who is the insider selling CORT shares and what is their role?

The seller is Sean Maduck, identified in prior sales disclosures as a company executive (listed address: Redwood City, CA).

How many CORT shares has the insider sold recently?

Over the last three months the insider sold 64,403 shares for roughly $4.79 million.

What percentage of Corcept’s outstanding shares does the proposed sale represent?

About 0.02 % of the 106.04 million shares outstanding.

When were the shares acquired before the planned sale?

They were acquired via stock-option exercise on 01 Aug 2025.